Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Neoplasms 2Hematologic Neoplasms 2Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Klebsiella Infections 1Gram-Positive Bacterial Infections 1Febrile Neutropenia 1Escherichia coli Infections 1Bacterial Infections 1Anemia, Refractory, with Excess of Blasts 1

Interventions

pembrolizumab 134Gemcitabine 101Paclitaxel 100Carboplatin 85Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 58Pemetrexed 51Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Piperacillin, Tazobactam Drug Combination × Clear all
NCT02732327 2017-07-21

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Forest Laboratories

Phase 2 Terminated
2 enrolled 2 charts
Classical hematology

Neoplasms, Febrile Neutropenia

NCT00044759 2007-10-10

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡